MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-11-2026
Evofem Biosciences Net Debt 2011-2026 | EVFM
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Evofem Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -396 K | -652 K | -475 K | 2.68 M | -976 K | 28.7 M | -15.4 M | 2.68 M | -3.42 M | -11.5 M | -27.8 M | -66.2 M | -4.16 M | -10.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28.7 M | -66.2 M | -7.66 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
14.7 M | $ 3.56 | 2.01 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 0.79 | -0.79 % | $ 4.31 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | USA |
 |
argenx SE
ARGX
|
-89.9 M | $ 703.3 | 0.41 % | $ 25 B |  Niderland |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-195 M | $ 231.03 | 2.23 % | $ 5 B |  Danmark |
 |
ADC Therapeutics SA
ADCT
|
-459 M | $ 4.22 | 2.18 % | $ 105 M |  Schweiz |
 |
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.61 | 0.28 % | $ 8.69 B |  Australia |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-206 M | $ 6.63 | -0.75 % | $ 182 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-46 M | $ 14.36 | 1.13 % | $ 210 M | USA |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 90.54 | -0.71 % | $ 27.2 B | Germany |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Burford Capital Limited
BUR
|
-135 M | $ 8.05 | 1.64 % | $ 1.31 B | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-48 M | - | - | $ 521 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-63.1 M | $ 6.05 | -0.82 % | $ 493 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-19.9 M | $ 2.64 | 3.94 % | $ 16.6 M | USA |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
 |
BioCardia
BCDA
|
212 K | $ 1.27 | 0.79 % | $ 26.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.51 | 4.86 % | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.58 | -0.56 % | $ 7.79 B | Israel |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
-72.3 M | $ 1.11 | - | $ 33.4 M | USA |